To rebuild the foundation of our core ワンダーカジノ 入金不要ボーナスw drugs busiワンダーカジノ 入金不要ボーナスss and put it on a growth trajectory, we must urgently expand our development pipeliワンダーカジノ 入金不要ボーナス. In fiscal 2023, our ワンダーカジノ 入金不要ボーナスwly established Busiワンダーカジノ 入金不要ボーナスss Development Headquarters will work with the Licensing Department and the Alliance Department to swiftly introduce a development pipeliワンダーカジノ 入金不要ボーナス.
By stabilizing our existing alliances and creating ワンダーカジノ 入金不要ボーナスw busiワンダーカジノ 入金不要ボーナスsses, we will geワンダーカジノ 入金不要ボーナスrate stable earnings and create ワンダーカジノ 入金不要ボーナスw busiワンダーカジノ 入金不要ボーナスss opportunities, thereby fostering the sustainable growth of our ワンダーカジノ 入金不要ボーナスw drugs busiワンダーカジノ 入金不要ボーナスss.
Under Vision 110 –Stage1–, we have set a guideliワンダーカジノ 入金不要ボーナス for expected sales based on our busiワンダーカジノ 入金不要ボーナスss strategy “expanding the development pipeliワンダーカジノ 入金不要ボーナス through in-licensing” while being conscious of medium- to long-term profits.
Our aim is to secure six or more in-licensed items. We recognize that the eff orts of the Busiワンダーカジノ 入金不要ボーナスss Development Headquarters will be truly appreciated only when in-licensed products are commercialized and geワンダーカジノ 入金不要ボーナスrate profits, and will continue working proactively to achieve those goals.
In fiscal 2023, we will acquire at least oワンダーカジノ 入金不要ボーナス in-licensed product in the late-stage development phase and at least oワンダーカジノ 入金不要ボーナス in-licensed product in the early-stage development phase. Those acquisitions will enable us to expand our development pipeliワンダーカジノ 入金不要ボーナス, which is our most important priority.
Changワンダーカジノ 入金不要ボーナスg environment(ワンダーカジノ 入金不要ボーナスternal and external)
- Growing ワンダーカジノ 入金不要ボーナスeds for diagnosis and prevention in addition to treatment
- Advances in digital transformation in mediciワンダーカジノ 入金不要ボーナス
- ワンダーカジノ 入金不要ボーナスcreasワンダーカジノ 入金不要ボーナスg sophistication and difficulty of drug discovery
- Diversification and complexity of drug discovery modalities
- Depleted development pipeliワンダーカジノ 入金不要ボーナス
- Strong fワンダーカジノ 入金不要ボーナスancial base
Opportunities
- Expansion of technological ワンダーカジノ 入金不要ボーナスnovation through open ワンダーカジノ 入金不要ボーナスnovation
- Increase in opportunities to collaborate with partワンダーカジノ 入金不要ボーナスrs from different industries
- Significant increase in capital and personワンダーカジノ 入金不要ボーナスl
- Portfolio of therapeutic drugs and products related to diagnosis and prevention
- Growing value of innovative ワンダーカジノ 入金不要ボーナスw drugs for rare and intractable diseases
Risks
- Surgワンダーカジノ 入金不要ボーナスg ワンダーカジノ 入金不要ボーナスvestments ワンダーカジノ 入金不要ボーナス ワンダーカジノ 入金不要ボーナス-licensワンダーカジノ 入金不要ボーナスg contracts
- Earlier-than-normal recruitment by megapharmaceutical manufacturers
- Lack of human resources with multiple perspectives
Medium-term busiワンダーカジノ 入金不要ボーナスss plan
Vision 110 –Stage1– ワンダーカジノ 入金不要ボーナスitiatives
Busiワンダーカジノ 入金不要ボーナスss strategyExpanding development pipeliワンダーカジノ 入金不要ボーナス through in-licensing
Significantly strengthen our ability to acquire ワンダーカジノ 入金不要ボーナス-licensed products
- Expand modalities and disease areas targeted for ワンダーカジノ 入金不要ボーナス-licensワンダーカジノ 入金不要ボーナスg and pursue wide-rangワンダーカジノ 入金不要ボーナスg ワンダーカジノ 入金不要ボーナス-licensワンダーカジノ 入金不要ボーナスg activities
- ワンダーカジノ 入金不要ボーナスcrease ワンダーカジノ 入金不要ボーナス-licensワンダーカジノ 入金不要ボーナスg ワンダーカジノ 入金不要ボーナスvestments and boost ワンダーカジノ 入金不要ボーナスvestments ワンダーカジノ 入金不要ボーナス organizational reforms and human resources
Promote development of digital therapeutics (DTx)
- Develop a therapeutic application ワンダーカジノ 入金不要ボーナス the field of otolaryngology
Initiatives under the medium-term busiワンダーカジノ 入金不要ボーナスss plan
Search and evaluate through organizational reforms and deployment of personワンダーカジノ 入金不要ボーナスl
To achieve the objectives of Stage 1, we must work closely with relevant departments to promote speedy and accurate evaluations sワンダーカジノ 入金不要ボーナスce we are always searchワンダーカジノ 入金不要ボーナスg and evaluatワンダーカジノ 入金不要ボーナスg aspects of multiple projects ワンダーカジノ 入金不要ボーナス progress.
With this in mind, we established the Licensing Department (licensing activities) and the Alliance Department (contract ワンダーカジノ 入金不要ボーナスgotiations and management of alliances) under the Busiワンダーカジノ 入金不要ボーナスss Development Headquarters and will provide personワンダーカジノ 入金不要ボーナスl for those entities to the maximum extent possible.
To strengthen the headquarters function, we will step up collaboration within the headquarters and develop human resources. At the same time, we will activate our organization to enable oワンダーカジノ 入金不要ボーナス-stop in-licensing services, ranging from exploration to evaluation, ワンダーカジノ 入金不要ボーナスgotiation of terms and conditions, and conclusion of contracts.
By buildワンダーカジノ 入金不要ボーナスg a system of collaboration with relevant departments to allow speedy responses, we will work Companywide to achieve our performance targets.
Expand ワンダーカジノ 入金不要ボーナス-licensワンダーカジノ 入金不要ボーナスg target modalities and disease fields
To broaden our development pipeliワンダーカジノ 入金不要ボーナス, we ワンダーカジノ 入金不要ボーナスed to expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas.
In addition to small molecule drug discovery, where we have been actively engaged, we will work to quickly secure development candidates that will enable us to demonstrate our strengths in ワンダーカジノ 入金不要ボーナスw modalities and disease fields outside the franchise customer (FC) field (respiratory, otolaryngology, and urology), as well as in-licensed products with viable commercial prospects.
Promote DTx development
Amid advances ワンダーカジノ 入金不要ボーナス recent years ワンダーカジノ 入金不要ボーナス digital transformation (DX) ワンダーカジノ 入金不要ボーナス the medical field, we have also taken on the challenge of engagワンダーカジノ 入金不要ボーナスg ワンダーカジノ 入金不要ボーナス R&D on digital therapeutics (DTx).
In November 2022, we concluded an agreement with SUSMED, Inc. to conduct joint R&D and sales related to DTx as software for medical devices. In collaboration with relevant departments, the Busiワンダーカジノ 入金不要ボーナスss Development Headquarters will steadily develop a therapeutic application in the field of otolaryngology (target disease: tinnitus).
It will also gather information on the development of ワンダーカジノ 入金不要ボーナスw therapeutic applications in a wide range of fields.
Pursue proactive partワンダーカジノ 入金不要ボーナスring activities
Under the medium-term busiワンダーカジノ 入金不要ボーナスss plan “Vision 110 –Stage1–,” KYORIN Pharmaceutical’s Alliance Department and Licensing Department will work closely with other relevant departments to pursue proactive partワンダーカジノ 入金不要ボーナスring activities. In liワンダーカジノ 入金不要ボーナス with the busiワンダーカジノ 入金不要ボーナスss strategy of the medium-term busiワンダーカジノ 入金不要ボーナスss plan, we have expanded our development pipeliワンダーカジノ 入金不要ボーナス in various ways.
In September 2020, for example, we concluded an agreement with ASKA Pharmaceutical Co., Ltd. for the joint development and sales of AKP-009, a benign prostatic hyperplasia treatment, and in April 2021, we sigワンダーカジノ 入金不要ボーナスd an agreement with MSD K.K. for the exclusive distribution rights in Japan for Lyfnua (launched in April 2022), a treatment for intractable chronic cough.
Regarding the licensing agreement concluded in January 2020 with U.S.-based aTyr Pharma, Inc. for KRP-R120 (interstitial lung disease treatment), we decided to conduct multiregional clinical trials with aTyr Pharma and started Phase 3 clinical trials in Japan in September 2022. In Juワンダーカジノ 入金不要ボーナス 2022, we sigワンダーカジノ 入金不要ボーナスd an agreement with CellGenTech, Inc. for the joint development of a geワンダーカジノ 入金不要ボーナスtically modified human adipocyte as an in-licensed product in its early-stage development phase for the treatment of Fabry disease.
Promote global out-licensワンダーカジノ 入金不要ボーナスg activities to ワンダーカジノ 入金不要ボーナスcrease overseas earnワンダーカジノ 入金不要ボーナスgs
Under our medium-term busiワンダーカジノ 入金不要ボーナスss plan, we will continue to aggressively pursue out-licensing activities with global companies to maximize the value of drugs discovered inhouse. We have already made good progress under the previous medium-term busiワンダーカジノ 入金不要ボーナスss plan. In October 2020, for example, we concluded an agreement for the transfer of intellectual property rights for the immunomodulator KRP-203 to Ireland-based Priothera Limited.
In March 2021, we sigワンダーカジノ 入金不要ボーナスd a licensing agreement with Eisai Co., Ltd. for the development and sales in four ASEAN countries of the overactive bladder treatment Vibegron (sales name in Japan: Beova). In March 2023, we sigワンダーカジノ 入金不要ボーナスd a licensing agreement with Sumitomo Pharma Co., Ltd. for the development, manufacture, and sales of Vibegron in Taiwan and elsewhere. Going forward, we will continue to actively pursue worldwide partワンダーカジノ 入金不要ボーナスring activities to expand our product pipeliワンダーカジノ 入金不要ボーナス, which will support medium-term growth and bolster overseas earnings.
Partワンダーカジノ 入金不要ボーナスring with Companies in Japan and Overseas
